K. Papamichael

发表

The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy.

A. Cheifetz, A. Goldowsky, Steven C Lin, 2018, Inflammatory bowel diseases.

Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse

P. Rutgeerts, S. Vermeire, A. Gils, 2015, Inflammatory bowel diseases.

Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.

P. Rutgeerts, S. Vermeire, A. Gils, 2016, Journal of Crohn's & colitis.

Review article: pharmacological aspects of anti‐TNF biosimilars in inflammatory bowel diseases

S. Vermeire, T. Van Stappen, A. Gils, 2015, Alimentary pharmacology & therapeutics.

Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation.

Shreya Amin, A. Cheifetz, K. Papamichael, 2018, Clinical immunology.

Cytokines and Insulin Resistance after Zoledronic Acid-Induced Acute Phase Response

H. Karga, F. Papandroulaki, K. Papamichael, 2014, Immunological investigations.

Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort.

Diana M. Negoescu, B. Vaughn, A. Cheifetz, 2019, Inflammatory bowel diseases.

Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence.

P. Rutgeerts, S. Vermeire, G. D'Haens, 2014, Journal of Crohn's & colitis.

Effect of Consent and Educational Adjuncts to Consent on Patient Perceptions About Colonoscopy

Varun Rao, D. Leffler, K. Papamichael, 2019, Journal of clinical gastroenterology.

Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.

H. Karga, G. Papaioannou, K. Papamichael, 2011, Metabolism: clinical and experimental.

Helicobacter pylori infection and inflammatory bowel disease: is there a link?

G. Mantzaris, K. Papamichael, P. Konstantopoulos, 2014, World journal of gastroenterology.

Osteoporosis in primary biliary cholangitis

E. Tapper, A. Bonder, K. Papamichael, 2018, World journal of gastroenterology.

Efficacy and Safety Profile of Anti-tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons.

A. Gils, E. Zintzaras, G. Mantzaris, 2016, Clinical therapeutics.

Choosing the right biologic for complications of inflammatory bowel disease

A. Cheifetz, K. Papamichael, S. Rakowsky, 2022, Expert review of gastroenterology & hepatology.

Has the time been reached for pseudopolyps to be re-enrolled in endoscopic inflammatory bowel disease scores?

M. Saridi, K. Katsanos, D. Christodoulou, 2019, World journal of gastrointestinal endoscopy.

A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn’s disease

L. Peyrin-Biroulet, G. Mantzaris, K. Papamichael, 2016, Expert opinion on drug safety.

Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis

V. Jairath, A. Cheifetz, M. Osterman, 2020, The American journal of gastroenterology.

Management of variceal bleeding

K. Goumas, C. Petrogiannopoulos, K. Papamichael, 2004 .

Targeted Physician Education and Standardizing Documentation Improves Documented Reporting with Inflammatory Bowel Disease Quality Measures in a Large Academic and Private Practice

D. Leffler, A. Cheifetz, K. Papamichael, 2017, Digestive Diseases and Sciences.

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

M. Dubinsky, C. Siegel, E. Loftus, 2021, The American journal of gastroenterology.

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.

G. Kaplan, L. Baidoo, S. Devlin, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease

B. Vaughn, A. Cheifetz, K. Papamichael, 2018, Digestive Diseases and Sciences.

Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus—A Multicenter Retrospective Study

S. Vermeire, M. Ferrante, U. Kopylov, 2017, Inflammatory bowel diseases.

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis

P. Rutgeerts, S. Vermeire, A. Gils, 2017, Journal of Crohn's & colitis.

AJG-20-3986 2014..2025

M. Dubinsky, C. Siegel, W. Afif, 2022 .

Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection

K. Garey, C. Kelly, N. Pollock, 2021, Open forum infectious diseases.

Helicobacter pylori infection and endocrine disorders: is there a link?

H. Karga, G. Mantzaris, G. Papaioannou, 2009, World journal of gastroenterology.

Association of TNF and FcγRΙΙΙA gene polymorphisms with differential response to infliximab in a Greek cohort of Crohn’s disease patients

M. Gazouli, G. Mantzaris, K. Papamichael, 2011, Annals of gastroenterology.

Evidence Supporting High-Dose Use of Biologics in Clinical Practice

A. Cheifetz, K. Papamichael, Sarah E. Shannahan, 2020, Current Treatment Options in Gastroenterology.

Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies

A. Cheifetz, K. Papamichael, 2021, Expert opinion on drug metabolism & toxicology.

Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient

L. Peyrin-Biroulet, S. Danese, A. Spinelli, 2021, Journal of clinical medicine.

Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease

A. Cheifetz, K. Papamichael, S. Rakowsky, 2021, Alimentary pharmacology & therapeutics.

Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay

S. Flier, A. Cheifetz, G. Melmed, 2020, Journal of clinical medicine.

Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.

A. Cheifetz, K. Papamichael, 2020, Current opinion in rheumatology.

How, When, and For Whom Should We Perform Therapeutic Drug Monitoring?

M. Dubinsky, S. Vermeire, E. Dreesen, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study.

C. Siegel, P. Irving, A. Cheifetz, 2019, Inflammatory bowel diseases.

Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?

A. Cheifetz, K. Papamichael, 2019, Gastroenterology.

Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases

J. Lambert, G. Wolbink, A. Cheifetz, 2019, Expert review of clinical immunology.

Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease.

B. Vaughn, A. Cheifetz, K. Papamichael, 2019, Journal of Crohn's & colitis.

Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease.

A. Cheifetz, M. Osterman, K. Papamichael, 2018, Inflammatory bowel diseases.

Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease

Ravy K. Vajravelu, B. Vaughn, A. Cheifetz, 2018, Journal of Crohn's & colitis.

Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?

M. Dubinsky, S. Hanauer, C. Siegel, 2018, Gastroenterology.

Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis

A. Cheifetz, M. Osterman, K. Papamichael, 2018, Alimentary pharmacology & therapeutics.

Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease

Ravy K. Vajravelu, A. Cheifetz, M. Osterman, 2018, Digestive Diseases and Sciences.

Improved Long‐term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

Ravy K. Vajravelu, B. Vaughn, A. Cheifetz, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.

C. Siegel, A. Cheifetz, T. Ullman, 2017, Inflammatory bowel diseases.

Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.

A. Gils, M. Ferrante, A. Cheifetz, 2017, Inflammatory bowel diseases.

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.

P. Rutgeerts, S. Vermeire, T. Van Stappen, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Use of anti-TNF drug levels to optimise patient management

A. Cheifetz, K. Papamichael, 2016, Frontline Gastroenterology.

Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.

P. Rutgeerts, S. Vermeire, A. Gils, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response.

M. Sparrow, X. Roblin, P. Riviere, 2019, Journal of Crohn's & colitis.

Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?

A. Cheifetz, K. Papamichael, 2019, Current opinion in gastroenterology.

Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.

A. Gils, M. Ferrante, A. Cheifetz, 2017, Inflammatory bowel diseases.

Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease.

S. Vermeire, K. Papamichael, 2015, World journal of gastroenterology.

Infliximab in inflammatory bowel disease

A. Cheifetz, K. Papamichael, Lindsey Sattler, 2019, Therapeutic advances in chronic disease.

Long term safety and efficacy of H1N1 vaccine in a single-center cohort of IBD patients treated with immunomodulators and/or anti-TNFα biologics.

N. Kyriakos, G. Mantzaris, K. Papamichael, 2012, Journal of Crohn's & colitis.

Bone of Contention: Helicobacter pylori and Osteoporosis—Is There an Association?

A. Cheifetz, K. Papamichael, Garyfallia Papaioannou, 2019, Digestive Diseases and Sciences.

Antiglycan Antibodies in Greek Patients with Inflammatory Bowel Disease

E. Kouroumalis, I. Koutroubakis, G. Mantzaris, 2010, Digestive Diseases and Sciences.

A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab

K. Petraki, G. Mantzaris, K. Papamichael, 2009, European journal of gastroenterology & hepatology.

Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.

G. Mantzaris, K. Papamichael, E. Archavlis, 2012, Journal of Crohn's & colitis.

A Lyophilized Form of Saccharomyces Boulardii Enhances the Helicobacter pylori Eradication Rates of Omeprazole-Triple Therapy in Patients With Peptic Ulcer Disease or Functional Dyspepsia

N. Kyriakos, G. Mantzaris, K. Papamichael, 2013 .

Response to Reinink

A. Cheifetz, K. Papamichael, 2017, The American Journal of Gastroenterology.

Autoimmune liver disease

K. Goumas, C. Petrogiannopoulos, K. Papamichael, 2007 .

The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy

G. Mantzaris, K. Papamichael, P. Karatzas, 2015, Scandinavian journal of gastroenterology.

The effects of recombinant human TSH on bone turnover in patients after thyroidectomy

H. Karga, P. Papaioannou, G. Papaioannou, 2009, Journal of Bone and Mineral Metabolism.

European experience with methotrexate treatment in Crohn’s disease: a multicenter retrospective analysis

U. Kopylov, C. J. van der Woude, G. Fiorino, 2016, European journal of gastroenterology & hepatology.

Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study.

U. Kopylov, G. Fiorino, P. Lakatos, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Pancreatic enzyme supplementation versus placebo for improvement of gastrointestinal symptoms in non-responsive celiac disease: A cross-over randomized controlled trial

J. Silvester, D. Leffler, C. Kelly, 2023, Frontiers in Medicine.

Histamine modulates the cellular stress response in yeast

E. Tiligada, K. Papamichael, B. Delitheos, 2009, Amino Acids.

Blood lymphocyte blastogenesis in patients with thyroid dysfunction: ex vivo response to mitogen activation and cyclosporin A

E. Tiligada, H. Karga, G. Papaioannou, 2010, Inflammation Research.

A Systematic Review on the interest of Drug Tolerant assay in the monitoring of Inflammatory Bowel Disease.

L. Waeckel, S. Paul, A. Cheifetz, 2022, Journal of Crohn's & colitis.

Therapeutic Drug Monitoring of Biologics in Crohn's Disease.

A. Cheifetz, K. Papamichael, Laurie B. Grossberg, 2022, Gastroenterology clinics of North America.

Review article: emerging drug therapies in inflammatory bowel disease

A. Cheifetz, K. Papamichael, Laurie B. Grossberg, 2022, Alimentary pharmacology & therapeutics.

Molybdate induces thermotolerance in yeast

E. Tiligada, K. Papamichael, A. Delitheos, 1999, Letters in applied microbiology.

Effect of the Hsp90 modulators on the heat-shock response in eukaryotic cells

E. Tiligada, K. Papamichael, E. Stavrinidis, 2008, Folia Microbiologica.

Simethicone adjunct to polyethylene glycol improves small bowel capsule endoscopy imaging in non-Crohn’s disease patients

G. Mantzaris, K. Papamichael, P. Karatzas, 2015, Annals of gastroenterology.

Clinical profiles of moderate and severe Crohn’s disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines

I. Koutroubakis, G. Mantzaris, K. Papamichael, 2015, Annals of gastroenterology.

Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)

M. Dubinsky, B. Sands, C. Siegel, 2022, BMJ Open.

Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies.

K. Katsanos, D. Christodoulou, A. Cheifetz, 2019, Clinical immunology.

European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease

J. Gisbert, E. Louis, L. Lopetuso, 2018, Journal of Crohn's & colitis.

Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease.

A. Cheifetz, K. Papamichael, 2016, Journal of Crohn's & colitis.

Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation

S. Vermeire, T. Van Stappen, A. Gils, 2016, Clinical and translational gastroenterology.

Pathogenesis of Helicobacter Pylori Infection: Colonization, Virulence Factors of the Bacterium and Immune and Non-immune Host Response

G. Mantzaris, K. Papamichael, 2012 .

Reply to Dr. Yamamoto's letter.

G. Mantzaris, K. Papamichael, 2013, Journal of Crohn's & colitis.

Patients with Low Drug Levels or Antibodies to a Prior Anti-TNF Are More Likely to Develop Antibodies to a Subsequent Anti-TNF.

M. Silverberg, F. Rieder, S. Flier, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.

S. Vermeire, I. Cleynen, M. Ferrante, 2015, Journal of Crohn's & colitis.

Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH Trial

M. Dubinsky, A. Cheifetz, K. Papamichael, 2022, The American journal of gastroenterology.

AJG-22-1918 485..490

M. Dubinsky, A. Cheifetz, K. Papamichael, 2022 .

Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation

I. Koulouridis, K. Katsanos, D. Christodoulou, 2019, Annals of gastroenterology.

Laxative use does not preclude diagnosis or reduce disease severity in Clostridiodes difficile infection.

C. Kelly, N. Pollock, K. Papamichael, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease

R. Cross, B. Vaughn, A. Cheifetz, 2020, Journal of clinical medicine.

A Survey Study of Gastroenterologists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD.

A. Cheifetz, F. Farraye, K. Papamichael, 2020, Inflammatory bowel diseases.

Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series

J. Shapiro, D. Treaba, A. Cheifetz, 2021, Digestive Diseases and Sciences.

Letter: is blindly stopping thiopurines without confirming adequate anti‐TNF concentrations shortsighted?

A. Cheifetz, K. Papamichael, N. Sousa Freitas Queiroz, 2022, Alimentary Pharmacology and Therapeutics.

Serum protein profile of Crohn's disease treated with infliximab.

A. Vaiopoulou, M. Gazouli, G. Tsangaris, 2013, Journal of Crohn's & colitis.

Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment

G. Silversmit, S. Vermeire, M. Ferrante, 2017, European journal of gastroenterology & hepatology.

Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.

A. Cheifetz, K. Papamichael, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy

A. Cheifetz, K. Papamichael, 2017, World journal of gastroenterology.

Letter: infliximab concentrations during induction therapy—one size does not fit all

A. Cheifetz, K. Papamichael, 2018, Alimentary pharmacology & therapeutics.

Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy

Konstantinos Papamichael, A. Cheifetz, K. Papamichael, 2017, The American Journal of Gastroenterology.

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease

M. Saridi, K. Katsanos, D. Christodoulou, 2021, Annals of gastroenterology.

Low prevalence of antibodies to cyclic citrullinated peptide in patients with inflammatory bowel disease regardless of the presence of arthritis

G. Mantzaris, K. Papamichael, A. Tsirogianni, 2009, European journal of gastroenterology & hepatology.

Anticancer drugs as inducers of thermotolerance in yeast

E. Tiligada, K. Papamichael, A. Delitheos, 2008, Folia Microbiologica.

DOP45 Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial

A. Cheifetz, M. Osterman, K. Papamichael, 2019, Journal of Crohn's and Colitis.

De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease.

G. Mantzaris, K. Papamichael, P. Karatzas, 2016, Journal of Crohn's & colitis.

Spontaneous retroperitoneal abscess caused by streptococcus pyogenes

A. Zaharof, C. Petrogiannopoulos, G. Hartzoulakis, 2004 .

Autoimmune Cholangitis Presented as Fever of Unknown Origin

K. Papamichael, I. Karachaliou, G. Karachalios, 2006, Chemotherapy.

Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases

G. Stocco, K. Papamichael, A. Ruiz del Agua, 2023, Therapeutic drug monitoring.

Predictors of post-colonoscopy emergency department use.

V. Novack, D. Leffler, K. Papamichael, 2017, Gastrointestinal endoscopy.

Proactive therapeutic drug monitoring of adalimumab in patients with Crohn's disease.

M. Dubinsky, A. Cheifetz, K. Papamichael, 2022, Gastroenterology.

Editorial: golimumab thresholds to achieve stringent medium‐ and long‐term therapeutic outcomes in patients with ulcerative colitis

G. Mantzaris, K. Papamichael, 2022, Alimentary pharmacology & therapeutics.

A subset of histamine receptor ligands improve thermotolerance of the yeast Saccharomyces cerevisiae

E. Tiligada, K. Papamichael, B. Delitheos, 2013, Journal of applied microbiology.

Faecal calprotectin but not C-reactive protein (CRP) or Crohn's Disease Activity Index (CDAI) may predict post-operative endoscopic recurrence of Crohn's disease.

G. Mantzaris, K. Papamichael, P. Karatzas, 2013, Journal of Crohn's & colitis.

Patients over Age 75 Are at Increased Risk of Emergency Department Visit and Hospitalization Following Colonoscopy

D. Leffler, K. Papamichael, M. Sawhney, 2019, Digestive Diseases and Sciences.

Histological healing beyond endoscopic healing in ulcerative colitis: Shall we target the "ultra-deep" remission?

K. Katsanos, D. Christodoulou, A. Cheifetz, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Granular cell tumour in a patient with Crohn's disease treated with infliximab: coincidence or causal relationship?

G. Mantzaris, K. Papamichael, A. Tsigka, 2012, European journal of gastroenterology & hepatology.

Editorial: is there a role for monitoring intermediate anti‐TNF drug concentrations in IBD?

A. Cheifetz, K. Papamichael, S. Rakowsky, 2022, Alimentary Pharmacology and Therapeutics.

Comparison between assays used for therapeutic drug monitoring of infliximab and adalimumab in inflammatory bowel disease.

C. Siegel, P. Irving, A. Cheifetz, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Integrin Calculus: The Predictive Power of Vedolizumab Concentrations in IBD Therapy

A. Cheifetz, K. Papamichael, 2019, Digestive Diseases and Sciences.

A primer on common supplements and dietary measures used by patients with inflammatory bowel disease

A. Cheifetz, K. Papamichael, R. Gianotti, 2023, Therapeutic advances in chronic disease.

Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.

K. Katsanos, D. Christodoulou, A. Cheifetz, 2018, Inflammatory Bowel Diseases.

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease

L. Waeckel, A. Cheifetz, X. Roblin, 2023, Journal of clinical medicine.

Circumvention of camptothecin-induced resistance during the adaptive cellular stress response.

E. Tiligada, K. Papamichael, A. Delitheos, 2006, Anticancer research.

Author’s reply to performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients: disease activity as an influencing factor

G. Mantzaris, K. Papamichael, 2016, Scandinavian journal of gastroenterology.